In HER2-Negative Metastatic Breast Cancer, Adding CDK4/6 Inhibitor to Endocrine Therapy Helps Survival

 Endocrine therapy plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improved overall survival, progression-free survival, and objective response rate for patients with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a meta-analysis published recently in JAMA Oncology. The finding supports continued use of endocrine therapy plus CDK4/6 inhibitor combinations in clinical trials. The investigators, led by first author Jinming Li, BD, a pr...
Continue reading

Advanced Breast Cancer: Adding Abemaciclib to Fulvestrant Improves Survival

​Updated results from MONARCH 2 report that adding abemaciclib (Verzenio®, Eli Lilly) to fulvestrant (Faslodex®, AstraZeneca) improves overall survival compared with fulvestrant alone in patients with endocrine-refractory hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. "Most patients with metastatic breast cancer have tumors that are HR-positive and are initially treated with endocrine therapy. Although endocrine therapy is an effi...
Continue reading

Tucidinostat (Chidamide)/Exemestane Effective in Breast Cancer

​A phase 3 clinical trial reports that tucidinostat (Epidaza®, Chipscreen Biosciences Ltd) in combination with exemestane (Aromasin®, Pfizer Inc.) improves progression-free survival compared with exemestane alone in postmenopausal patients with advanced, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer experiencing disease progression following prior endocrine therapy. Also known as chidamide, tucidinostat is an orally bioavailable subtype-se...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.